Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

Key Stats

• Today's Range: $8.77 to $9.69
• 50-Day Range: $5.88 to $10.73
• 52-Week Range: $4.20 to $34.27
• Volume: 67,286 shs
• Average Volume: 91,372 shs
• Market Capitalization: $78.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 20% of companies evaluated by MarketBeat, and ranked 762nd out of 844 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Scilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Scilex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently decreased by 11.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Scilex has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Scilex this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.50% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/20/2026
• Today: 7/09/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCLX
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($40.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$358.73 million
• Net Margins: -1,110.17%
• Pretax Margin: -1,162.36%
• Return on Equity: N/A
• Return on Assets: -143.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $30.25 million
• Price / Sales: 2.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($24.94) per share
• Price / Book: -0.37

Miscellaneous

• Outstanding Shares: 8,490,000
• Free Float: 8,109,000
• Market Cap: $78.48 million
• Optionable: No Data
• Beta: 1.66